Data Insights

Revumenib citrate by Syndax Pharmaceuticals for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

Revumenib citrate is under clinical development by Syndax Pharmaceuticals and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute...

Likelihood of Approval and Phase Transition Success Rate Model - Revumenib Citrate in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Data Insights

Revumenib citrate by Syndax Pharmaceuticals for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

Revumenib citrate is under clinical development by Syndax Pharmaceuticals and currently in Phase II for Relapsed Acute Myeloid Leukemia. According...

Likelihood of Approval and Phase Transition Success Rate Model - Revumenib Citrate in Relapsed Acute Myeloid Leukemia

Data Insights

Revumenib citrate by Syndax Pharmaceuticals for Refractory Acute Myeloid Leukemia: Likelihood of Approval

Revumenib citrate is under clinical development by Syndax Pharmaceuticals and currently in Phase II for Refractory Acute Myeloid Leukemia. According...

Likelihood of Approval and Phase Transition Success Rate Model - Revumenib Citrate in Refractory Acute Myeloid Leukemia

Data Insights

Revumenib citrate by Syndax Pharmaceuticals for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval

Revumenib citrate is under clinical development by Syndax Pharmaceuticals and currently in Pre-Registration for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic...

Likelihood of Approval and Phase Transition Success Rate Model - Revumenib Citrate in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Data Insights

Revumenib citrate by Syndax Pharmaceuticals for Solid Tumor: Likelihood of Approval

Revumenib citrate is under clinical development by Syndax Pharmaceuticals and currently in Phase II for Solid Tumor. According to GlobalData,...

Data Insights

Revumenib citrate by Syndax Pharmaceuticals for Metastatic Colorectal Cancer: Likelihood of Approval

Revumenib citrate is under clinical development by Syndax Pharmaceuticals and currently in Phase II for Metastatic Colorectal Cancer. According to...